IL1B and lung adenocarcinoma: Previous clinical study has revealed that the FZQX prescription could effectively reduce the levels of inflammatory factors (IL-6, TNF-α, IL-1β) and negative immune cells (Treg, MDSCs) in postoperative patients with early-stage lung adenocarcinoma and improve the quality of life [13].